ExicureXCUR -5.15%30 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates XCUR with a GF Score™ of 30/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Exicure ranks worse than 104166.56% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Exicure's Free Cash Flow for the
three
months ended in Mar. 2026 was $-1.14 Mil. Exicure's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Exicure's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Exicure's FCF Margin % or its related term are showing as below:
During the past 10 years, the highest FCF Margin % of Exicure was 7409.32%. The lowest was -16594.07%. And the median was -234.31%.
XCUR's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21 * Ranked among companies with meaningful FCF Margin % only.
Exicure FCF Margin % Related Terms
Exicure FCF Margin % Historical Data
* Premium members only.
The historical data trend for Exicure's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exicure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exicure FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exicure's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Exicure's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exicure (XCUR) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Exicure and its competitors. According to the industry distribution chart, Exicure ranks #999999 out of 960 companies in the Biotechnology industry.
Is Exicure's FCF Margin % too high?
Exicure's current FCF Margin % is 0.00%. Based on the distribution chart, Exicure ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Exicure has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exicure's FCF Margin % compare to GRTX and AEON?
According to the Biotechnology industry distribution chart, Exicure ranks #999999 out of 960 companies for FCF Margin %. This places Exicure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Exicure and its competitors. Exicure's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exicure stock overvalued right now?
Based on GuruFocus' analysis, Exicure (XCUR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $2.58 — trading 377.8% above its estimated fair value. The current FCF Margin % is 0.00%. Exicure's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Exicure (XCUR), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exicure (XCUR) Overvalued in 2026?
Based on GuruFocus' analysis, Exicure stock appears to be overvalued.
The current stock price of $2.58 is trading 377.8% above its estimated GF Value™ of $0.54.
GuruFocus considers Exicure to be Significantly Overvalued.
Key valuation signals for XCUR:
FCF Margin %: 0.00%
GF Value™: $0.54 vs. price of $2.58 (377.8% above fair value)
No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
30GF Score
Get the complete analysis for XCUR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCUR has been successfully added to your 
